



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/642,236	08/17/2000	George R. Schwartz	41145-1001	6972

7590 12/31/2002

Stephen A Slusher  
Peacock Myers & Adams P C  
P O Box 26927  
Albuquerque, NM 87125-6927

EXAMINER

KAM, CHIH MIN

ART UNIT	PAPER NUMBER
1653	16

DATE MAILED: 12/31/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	09/642,236	SCHWARTZ, GEORGE R.
	Examiner Chih-Min Kam	Art Unit 1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 26 September 2002.

2a) This action is **FINAL**.                    2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 23-61 is/are pending in the application.

4a) Of the above claim(s) 23-32 is/are withdrawn from consideration.

5) Claim(s) 61 is/are allowed.

6) Claim(s) 33-60 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

1) Notice of References Cited (PTO-892)                    4) Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_ .  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)                    5) Notice of Informal Patent Application (PTO-152)  
 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_ .                    6) Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Status of the Claims***

1. Claims 23-61 are pending.

Applicants' amendment filed on September 26, 2002 (Paper No. 15) is acknowledged.

Applicants' response has been fully considered. Claims 33 and 60 have been amended, claims 23-32 are non-elected claims and stand withdrawn from consideration. A new claim 61 has been added. Thus, claims 33-61 are examined.

### **Rejection Withdrawn**

### ***Claim Rejections - 35 USC § 112***

2. The previous rejection of claims 33-59 under 35 USC § 112, second paragraph, is withdrawn in view of applicants' amendment to the claim, and applicants' response at pages 3-5 in Paper No. 15.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 33, 34, 39-46 and 51-60 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of inducing regeneration and repair of nerve axon myelin coatings in a mammal, or a method of inducing increased platelet production with secondary increased endogenous production of platelet-derived growth factor (PDGF) to produce the effect of regenerating nerve axon myelin coatings in a mammal, the method comprising systemically administering thrombopoietin and thyroid hormone, or,

thrombopoietin, thyroid hormone and thyrotropin, does not reasonably provide enablement for a method of inducing regeneration and repair of nerve axon myelin coatings in a mammal, or a method of inducing increased platelet production with secondary increased endogenous production of platelet-derived growth factor in a mammal, the method comprising systemically administering thrombopoietin alone, or thrombopoietin and a thyroid regulatory agent. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Claims 33, 34, 39-46 and 51-60 are directed to a method of inducing regeneration and repair of nerve axon myelin coatings in a mammal, comprising systemically administering thrombopoietin and a thyroid regulatory agent (claims 33-34 and 39-44); a method of inducing increased platelet production with secondary increased endogenous production of platelet-derived growth factor in a mammal, the method comprising systemically administering thrombopoietin alone (claims 57-60), or thrombopoietin and a thyroid regulatory agent (claims 45, 46, 51-56). The specification, however, only discloses cursory conclusions without data supporting the findings, which states that the present invention provides a method for neuron and myelin regeneration using endogenous PDGF which is induced by use of an enhancement agent such as thrombopoietin, and a regulatory agent such as thyroid hormone or thyrotropin may be combined with the enhancement agent to regulate cell division and oligogendroglia production (pages 4-6). There are no indicia that the present application enables the full scope in view of a method of inducing regeneration and repair of nerve axon myelin coating or a method of inducing increased platelet production using thrombopoietin, or thrombopoietin and a regulatory

agent as discussed in the stated rejection. The present application provides no indicia and no teaching/guidance as to how the full scope of the claims is enabled. The factors considered in determining whether undue experimentation is required, are summarized in In re Wands (858 F2d at 731,737, 8 USPQ2d at 1400,1404 (Fed. Cir.1988)). The factors most relevant to this rejection are the breath of the claims, the absence of working examples, the state of the prior art and relative skill of those in the art, the unpredictability of the art, the nature of the art, the amount of direction or guidance presented, and the amount of experimentation necessary.

(1). The breath of the claims:

The breath of the claims is broad and encompasses unspecified variants regarding a thyroid regulatory agent, and the treating conditions for inducing regeneration and repair of nerve axon myelin coatings, or for inducing increased platelet production with secondary increased endogenous production of PDGF to produce the effect of regeneration of nerve axon myelin coatings using the thyroid regulatory agent with thrombopoietin, which are not adequately described or demonstrated in the specification.

(2). The absence or presence of working examples:

There are no working examples indicating the claimed methods in association with variants except for using thrombopoietin with thyroid hormone and thyrotropin, or, thrombopoietin and thyroid hormone (Examples 1-3).

(3). The state of the prior art and relative skill of those in the art:

The prior art, for example, Thomas (U. S. Patent 5,879,673) teaches administration of thrombopoietin at single or multiple doses is used to increase the number of platelet for treating thrombocytopenia; Grinspan *et al.* (Annals of neurology 36, S140-S142 (supplement) 1994)

teach PDGF stimulates the formation of oligodendroglia from partially differentiated progenitor cells, and loss of oligodendroglia is frequently found in demyelinative diseases; Rodriguez-Pena (J. Neurobiol. 40, 497-512 (1997)) teaches thyroid hormone regulates the number of oligodendrocyte generated by directly promoting their differentiation. However, the general knowledge and level of the skill in the art do not supplement the omitted description, the specification needs to provide specific guidance on the identities of various thyroid regulatory agents other than thyroid hormone and thyrotropin, and the treating conditions using these agents to be considered enabling for the claimed method.

(4). Predictability or unpredictability of the art:

The specification has shown using thrombopoietin with thyroid hormone and thyrotropin, or, thrombopoietin and thyroid hormone to induce regeneration and repair of nerve axon myelin coatings in an animal model (Examples 1-3). However, the specification does not provide the treating conditions using various thyroid regulatory agents nor indicates the effects of these agents, the invention is highly unpredictable regarding the effects of these agents in mammals.

(5). The amount of direction or guidance presented and the quantity of experimentation necessary:

The claims are directed to a method of inducing regeneration and repair of nerve axon myelin coatings in a mammal, comprising systemically administering thrombopoietin and a thyroid regulatory agent; a method of inducing increased platelet production with secondary increased endogenous production of platelet-derived growth factor to produce the effect of regeneration of nerve axon myelin coatings in a mammal, comprising systemically administering thrombopoietin alone, or thrombopoietin and a thyroid regulatory agent. However, the

specification has only shown using thrombopoietin with thyroid hormone and thyrotropin, or, thrombopoietin and thyroid hormone to induce regeneration and repair of nerve axon myelin coatings in animal models (Examples 1-3). There is no working example demonstrating the use of thrombopoietin alone, or thrombopoietin with any other thyroid regulatory agent than thyroid hormone in inducing regeneration and repair of nerve axon myelin coatings, or being able to produce the desired effect in a mammal. The specification has not provided the treating conditions such as the effective amount of a thyroid regulatory agent other than thyroid hormone, nor indicated the effects of these agents. Furthermore, there is no data indicating thrombopoietin alone would produce the desired effect. Since the specification fails to provide sufficient guidance on the identities of various thyroid regulatory agents, and the treating conditions and the effects of these agents, it is necessary to carry out further experimentation to assess the effects of various thyroid regulatory agents in inducing regeneration and repair of nerve axon myelin coatings in vivo.

(6). Nature of the Invention

The scope of the claims encompass using thrombopoietin, or thrombopoietin and a thyroid regulatory agent to induce regeneration and repair of nerve axon myelin coatings in a mammal, but the specification does not provide the treating conditions and the effects for various thyroid regulatory agents in the claimed method. Thus, the disclosure is not enabling for the reasons discussed above.

In summary, the scope of the claim is broad, the working example does not demonstrate the claimed methods, the art is unpredictable regarding the effects of various thyroid regulatory agents, and the guidance and the teaching in the specification are limited, therefore, it is

necessary to have additional guidance and to carry out further experimentation to assess the therapeutic effects of these thyroid regulatory agents.

***Claim Rejections - 35 USC §112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 35-40 and 47-52 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 35, for example is indefinite because of the use of the term “the thyroid regulatory agent comprises thyroid hormone”. The term “the thyroid regulatory agent comprises thyroid hormone” renders the claim indefinite, it is not clear what else is included in the thyroid regulatory agent besides thyroid hormone as to “comprises”. See also claims 37-39, 47 and 49-51. Claims 36, 40, 48 and 52 are included in the rejection because they are dependent on rejected claims and do not correct the deficiency of the claim from which they depend.

***Conclusion***

5. Claims 33-60 are rejected, and it appears claim 61 is free of prior art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, Ph. D. can be reached on (703) 308-2923. The fax phone numbers

for the organization where this application or proceeding is assigned are (703) 308-0294 for regular communications and (703) 308-4227 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D. *CK*  
Patent Examiner

\*\*\*

December 27, 2002

*Christopher S. Low*  
CHRISTOPHER S. F. LOW  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600